trial · primary record
Olaparib
Colorectal Neoplasms
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 268 |
| Primary completion | 2027-10-30 |
| Primary endpoint | Ph II Determine overall response rate of Durvalumab-O and Durvalumab-C in patients with recurrent ovarian cancer |
| Registry ID | NCT02484404 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:13.157Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02484404
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.